61.50
1.02 (1.69%)
| Previous Close | 60.48 |
| Open | 60.73 |
| Volume | 39,926 |
| Avg. Volume (3M) | 33,345 |
| Market Cap | 2,001,505,152 |
| Price / Book | 12.50 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Diluted EPS (TTM) | -1.36 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 25.98 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -33.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Belite Bio, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 1.13 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.93% |
| % Held by Institutions | 0.75% |
| 52 Weeks Range | ||
| Median | 100.00 (62.60%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 May 2025 | 100.00 (62.60%) | Buy | 67.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jul 2025 | Announcement | Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy |
| 21 May 2025 | Announcement | Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease |
| 13 May 2025 | Announcement | Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 12 May 2025 | Announcement | Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th |
| 12 May 2025 | Announcement | Belite Bio to Participate in Four Upcoming Investor Conferences |
| 07 May 2025 | Announcement | Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results |
| 29 Apr 2025 | Announcement | Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |